Point Therapeutics Announces Resignation of William Whelan from Board of Directors

  
    
  
  
    
      Point Therapeutics, Inc. (NASDAQ: POTP) today announced that because of 
      his other commitments and responsibilities, William J. Whelan, Jr. has 
      resigned from the Company’s Board of 
      Directors. Mr. Whelan has served on the Board since 1997.
    
    
      “We are very grateful for Bill’s 
      contributions, advice, and counsel in his 10 years of service to Point, 
      and I am joined by the other directors in wishing him very well,” 
      said Don Kiepert, President, Chairman, and CEO of Point Therapeutics.
    
    
      About Point Therapeutics, Inc.:
    
    
      Point is a Boston-based biopharmaceutical company which is currently 
      studying its lead product candidate, talabostat, in two Phase 3 double 
      blind placebo-controlled trials in non-small cell lung cancer and in a 
      Phase 2 trial in combination with gemcitabine in metastatic pancreatic 
      cancer. Point has also studied talabostat in several Phase 2 trials, 
      including as a single-agent in metastatic melanoma, in combination with 
      cisplatin in metastatic melanoma and in combination with rituximab in 
      advanced chronic lymphocytic leukemia.